Emergency Department Substance Use Surveillance System
ID: 356384Type: Posted
Overview

Buyer

Office of National Drug Control Policy (ONDCP)

Award Range

$0 - $150K

Eligible Applicants

Private Institutions of Higher Education

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356384

Additional Information

https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=113615
Timeline
    Description

    The Office of National Drug Control Policy (ONDCP) is offering a cooperative agreement for the Emergency Department Substance Use Surveillance System, aimed at enhancing drug early warning indicators through expanded testing methodologies. The project focuses on re-testing previously collected urine samples to identify a broader range of drugs, including emerging substances like xylazine and fentanyl, and aims to analyze these results in conjunction with electronic health records to improve drug exposure surveillance across various populations. This initiative is crucial for reinforcing best practices and standardizing testing in emergency departments nationwide. Interested applicants, specifically private institutions of higher education, should note that the funding ceiling is set at $150,000, with a submission deadline of September 17, 2024. For further inquiries, contact the Grants.gov Customer Support at 1-800-518-4726.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods," aimed at small businesses. This initiative seeks to develop innovative, cost-effective drug detection technologies capable of identifying both known and emerging drugs, such as xylazine and nitazenes, with sensitivity comparable to liquid chromatography-mass spectrometry (LC-MS). The program emphasizes the need for user-friendly devices that can facilitate on-site drug detection, thereby addressing public health challenges related to drug misuse. A total budget of approximately $3 million is available for four to seven grants, with applications due by January 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer (STTR) Grant, specifically under the R41/R42 program, aimed at developing innovative devices for the detection of new and existing drugs. This funding opportunity encourages small businesses to create cost-effective, user-friendly technologies that can detect drugs at the point-of-need, such as in emergency departments or harm reduction centers, utilizing target-agnostic methods that provide greater sensitivity and selectivity than traditional detection methods. With a total funding amount of $3 million available to support approximately four to seven projects, applications are due by February 19, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-23-054), aimed at supporting innovative research that bridges the gap between research findings and practical applications to combat the opioid overdose crisis. This initiative emphasizes the need for stigma-free, patient-centered care systems and focuses on understudied areas related to overdose prevention, requiring applicants to present preliminary data for significant projects within a maximum project period of five years and a budget of up to $750,000 in direct costs annually. The funding reflects a commitment to addressing health disparities and promoting effective addiction treatment and recovery solutions, with applications evaluated based on significance, innovation, feasibility, and stakeholder engagement. Interested applicants should note that the application deadline is March 20, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    First Responders – Comprehensive Addiction and Recovery Act
    Active
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is forecasting a grant opportunity titled "First Responders – Comprehensive Addiction and Recovery Act," aimed at supporting first responders and key community members in administering emergency treatments for opioid overdoses. This program is designed to enhance the capacity of eligible entities, including states, local governments, and tribal organizations, to utilize approved drugs or devices for the rapid reversal of opioid overdoses, addressing a critical public health issue. With an estimated total program funding of $5.1 million and an expected 12 awards, interested applicants can reach out to Shannon Hastings at (240) 276-1869 or via email at DTPFRCARA@samhsa.hhs.gov for further information. The synopsis for this opportunity is anticipated to be posted on November 15, 2024, with no cost-sharing or matching requirements.